Moderna Preparing for Global Launch of COVID-19 Vaccine, Ready to Ship 20 Million Doses by 2020 End

Moderna, Inc. (Cambridge, MA, USA) is preparing for the global launch of its COVID-19 vaccine and has already received deposits of over USD 1 billion from governments around the world.

In its third-quarter earnings report, Moderna informed that enrolment for the Phase 3 study of its COVID-19 vaccine candidate (mRNA-1273) had been completed with 30,000 participants. In addition to the Phase 3 study of its mRNA-1273 COVID-19 vaccine, the company expects to begin pivotal Phase 3 trial of its CMV vaccine candidate (mRNA-1647) in 2021.

Moderna expects to have about 20 million doses of its COVID-19 vaccine ready to ship in the US by the end of the year. The company has already entered into supply agreements for its COVID-19 vaccine in North America, the Middle East and other regions across the world.

“We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world. Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I believe that if we launch our COVID-19 vaccine, 2021 could be the most important inflection year in Moderna’s history.

“From a distribution standpoint, we’re ready,” Dr. Tal Zaks, Moderna’s chief medical officer, told investors on a conference call. “We expect mRNA-1273 to be distributed within existing infrastructure. There’s nothing new required that hasn’t already been used for years with many other vaccines.”

Related Links:
Moderna, Inc.